Last updated on January 2020

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia


Brief description of study

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To confirm tolerability of the combination regimen with the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of cancer and leukemia group B (CALGB) 10403.

II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free survival (EFS) in patients who achieve an induction response achieved with the pediatric-inspired regimen of CALGB 10403, without censoring for transplant. (Phase III)

SECONDARY OBJECTIVES:

I. To determine the impact of inotuzumab ozogamicin on disease-free (DFS) and overall survival (OS) in patients who achieve an induction response.

II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free survival (EFS) in patients who achieve an induction response achieved with the pediatric-inspired regimen of CALGB 10403, with censoring for transplant.

III. To determine the impact of inotuzumab ozogamicin on minimal residual disease (MRD) and correlate this with the EFS, DFS and OS.

IV. To determine the prognosis based on patients' low-density array (LDA) gene signature in terms of EFS, DFS, and OS after treatment with or without inotuzumab ozogamicin when added to the C10403 backbone regimen.

V. To evaluate the toxicity and tolerability of the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of CALGB 10403.

TERTIARY OBJECTIVES:

I. To assess both the correlation of MRD post-induction and at sequential timepoints with LDA signature.

II. To evaluate the influence of MRD status (detectable vs. not and as a continuous measure) in relation to EFS both in the univariate setting as well as adjusting for other clinical features including initial white blood cell (WBC), ethnicity, gender and age at diagnosis.

III. To evaluate the impact of inotuzumab ozogamicin (inotuzumab) on the kinetics of MRD during treatment with inotuzumab in patients randomized to the experimental treatment arm.

IV. To perform genomic analyses to identify and evaluate the incidence and clinical significance of recurring novel fusion genes including those associated with the BCR-ABL1-like signature and to correlate with MRD status, CR rate, EFS and OS.

V. To assess whether rs4958351 is correlated with L-asp allergic reaction in the adolescent and young adult (AYA) population.

VI. To assess the incidence of inherited genetic variants in the GR1A1, CEP72, CPA2, TPMT, NUDT15, GRIN3A, GRIK1, and other genes (which can be found using a whole genome association study [GWAS]), are correlated with increased rates of target toxicities including peripheral neuropathy, hepatotoxicity, pancreatitis, myelosuppression, neurotoxicity, thrombosis, and osteonecrosis, and correlate with treatment discontinuation and other clinical response parameters including complete response (CR) rate, EFS, and OS.

VII. To evaluate asparaginase pharmacokinetics in adolescents and young adults, and investigate its correlation with toxicities and treatment outcomes.

VIII. To investigate the effect of anti-polyethylene glycol (PEG) and anti-agouti signaling protein (ASP) antibodies (PEG-ASP) on ASP enzyme activity.

IX. To measure adherence to oral 6 mercaptopurine (MP) and methotrexate in AYAs with acute lymphoblastic leukemia (ALL) and to examine sociodemographic and behavioral determinants of adherence.

X. To determine the impact of adherence on risk of relapse among AYAs with ALL.

OUTLINE

COURSE I (REMISSION INDUCTION THERAPY): All patients receive allopurinol orally (PO) once daily until peripheral blasts and extramedullary disease are reduced and cytarabine intrathecally (IT) over 1 minute on day 1. Patients also receive daunorubicin hydrochloride intravenously (IV) and vincristine sulfate IV on days 1, 8, 15 and 22, dexamethasone PO or IV twice daily (BID) on days 1-7 and 15-21, pegylated L-aspiraginase IV on day 4, 5, or 6, and methotrexate IT over 1 minute on days 8 and 29. Patients with central nervous system (CNS) 3 disease receive methotrexate IT over 1 minute also on days 15 and 22. All patients then undergo bone marrow aspirate and biopsy on day 29.

Patients with response to remission induction therapy are randomized to 1 of 2 arms. Patients with no response are omitted from the study.

ARM I:

COURSE II (REMISSION CONSOLIDATION CHEMOTHERAPY): Patients receive cyclophosphamide IV on days 1 and 29, cytarabine IV or SC on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14 and 29-42, and vincristine sulfate IV on days 15, 22, 43, and 50. Patients also receive pegylated L-aspiraginase IV on days 15 and 43, and methotrexate IT on days 1, 8, 15, and 22. Patients with CNS3 receive methotrexate IT only on days 1 and 8. CD20 positive (+) patients receive rituximab IV on days 1, 8, 29, and 36. Patients then undergo bone marrow aspirate and biopsy on day 56.

COURSE III (INTERIM MAINTENANCE CHEMOTHERAPY): Patients receive vincristine sulfate IV on days 1, 11, 21, 31, and 41, methotrexate IV and IT on days 1, 11, 21, 31, and 41, and pegylated L-aspiraginase IV on days 2 and 22. CD20+ patients receive rituximab IV on days 1 and 11.

COURSE IV (DELAYED INTENSIFICATION): Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50, dexamethasone PO or IV BID on days 1-7 and 15-21, doxorubicin IV on days 1, 8, and 15, and pegylated L-aspiraginase IV on day 4, 5, or 6 and day 43. Patients also receive cyclophosphamide IV on day 29, cytarabine IV or SC on days 29-32 and 36-39, thioguanine PO on days 29-42 and methotrexate IT on days 1, 29, and 36. CD20+ patients receive rituximab IV on days 1 and 8. Patients then undergo bone marrow aspirate and biopsy on day 50.

COURSE V (MAINTENANCE THERAPY): Patients receive vincristine sulfate IV on days 1, 29, and 57, dexamethasone PO or IV BID on days 1-5, 29-33, and 57-61, and mercaptopurine PO on days 1-84. Patients also receive methotrexate IT or PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. Treatment repeats every 12 weeks for up to 3 years in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.

After completion of study treatment, patients are followed up every month for the first year, every 2 months for the second year, every 3 months for the third year, and every 6 months for the fourth through tenth year.

Clinical Study Identifier: NCT03150693

Find a site near you

Start Over

Medical Center of Baton Rouge

Baton Rouge, LA United States
  Connect »

Kootenai Cancer Center

Post Falls, ID United States
  Connect »

Mercy Hospital

Coon Rapids, MN United States
  Connect »

Saint Francis Cancer Center

Greenville, SC United States
  Connect »

Heartland Regional Medical Center

Saint Joseph, MO United States
  Connect »

Freeman Health System

Joplin, MO United States
  Connect »

Bay Area Hospital

Coos Bay, OR United States
  Connect »

Saint Joseph Mercy Hospital

Ann Arbor, MI United States
  Connect »

Ochsner Medical Center Jefferson

New Orleans, LA United States
  Connect »

Katmai Oncology Group

Anchorage, AK United States
  Connect »

Pocono Medical Center

East Stroudsburg, PA United States
  Connect »

Alaska Women's Cancer Care

Anchorage, AK United States
  Connect »

Anchorage Oncology Centre

Anchorage, AK United States
  Connect »

Mayo Clinic Hospital

Phoenix, AZ United States
  Connect »

Mayo Clinic in Arizona

Scottsdale, AZ United States
  Connect »

Mercy Hospital Fort Smith

Fort Smith, AR United States
  Connect »

Fresno Cancer Center

Fresno, CA United States
  Connect »

Kaiser Permanente-Redwood City

Redwood City, CA United States
  Connect »

Kaiser Permanente-Richmond

Richmond, CA United States
  Connect »

Rohnert Park Cancer Center

Rohnert Park, CA United States
  Connect »

Kaiser Permanente-Roseville

Roseville, CA United States
  Connect »

South Sacramento Cancer Center

Sacramento, CA United States
  Connect »

Kaiser Permanente - Sacramento

Sacramento, CA United States
  Connect »

Kaiser Permanente-San Francisco

San Francisco, CA United States
  Connect »

Kaiser Permanente-San Rafael

San Rafael, CA United States
  Connect »

Kaiser San Rafael-Gallinas

San Rafael, CA United States
  Connect »

Kaiser Permanente-Santa Rosa

Santa Rosa, CA United States
  Connect »

Kaiser Permanente Cancer Treatment Center

South San Francisco, CA United States
  Connect »

Kaiser Permanente-South San Francisco

South San Francisco, CA United States
  Connect »

Kaiser Permanente-Stockton

Stockton, CA United States
  Connect »

Kaiser Permanente-Vallejo

Vallejo, CA United States
  Connect »

Kaiser Permanente-Walnut Creek

Walnut Creek, CA United States
  Connect »

Yale University

New Haven, CT United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

University of Illinois

Chicago, IL United States
  Connect »

Blank Children's Hospital

Des Moines, IA United States
  Connect »

Iowa Methodist Medical Center

Des Moines, IA United States
  Connect »

Broadlawns Medical Center

Des Moines, IA United States
  Connect »

Iowa Lutheran Hospital

Des Moines, IA United States
  Connect »

Methodist West Hospital

West Des Moines, IA United States
  Connect »

Lawrence Memorial Hospital

Lawrence, KS United States
  Connect »

Wesley Medical Center

Wichita, KS United States
  Connect »

Ochsner Health Center-Summa

Baton Rouge, LA United States
  Connect »

Ochsner High Grove

Baton Rouge, LA United States
  Connect »

Bronson Battle Creek

Battle Creek, MI United States
  Connect »

Hurley Medical Center

Flint, MI United States
  Connect »

Mercy Health Saint Mary's

Grand Rapids, MI United States
  Connect »

Bronson Methodist Hospital

Kalamazoo, MI United States
  Connect »

West Michigan Cancer Center

Kalamazoo, MI United States
  Connect »

Borgess Medical Center

Kalamazoo, MI United States
  Connect »

Sparrow Hospital

Lansing, MI United States
  Connect »

Saint Mary Mercy Hospital

Livonia, MI United States
  Connect »

Mercy Health Mercy Campus

Muskegon, MI United States
  Connect »

Lakeland Hospital Niles

Niles, MI United States
  Connect »

Saint Joseph Mercy Oakland

Pontiac, MI United States
  Connect »

Marie Yeager Cancer Center

Saint Joseph, MI United States
  Connect »

Munson Medical Center

Traverse City, MI United States
  Connect »

Metro Health Hospital

Wyoming, MI United States
  Connect »

Fairview Ridges Hospital

Burnsville, MN United States
  Connect »

Miller-Dwan Hospital

Duluth, MN United States
  Connect »

Essentia Health - Fosston

Fosston, MN United States
  Connect »

Unity Hospital

Fridley, MN United States
  Connect »

Abbott-Northwestern Hospital

Minneapolis, MN United States
  Connect »

Hennepin County Medical Center

Minneapolis, MN United States
  Connect »

Health Partners Inc

Minneapolis, MN United States
  Connect »

Monticello Cancer Center

Monticello, MN United States
  Connect »

Essentia Health - Park Rapids

Park Rapids, MN United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, MN United States
  Connect »

Regions Hospital

Saint Paul, MN United States
  Connect »

United Hospital

Saint Paul, MN United States
  Connect »

Essentia Health Sandstone

Sandstone, MN United States
  Connect »

Lakeview Hospital

Stillwater, MN United States
  Connect »

Ridgeview Medical Center

Waconia, MN United States
  Connect »

Rice Memorial Hospital

Willmar, MN United States
  Connect »

Mercy Hospital South

Saint Louis, MO United States
  Connect »

Mercy Hospital Saint Louis

Saint Louis, MO United States
  Connect »

Mercy Hospital Springfield

Springfield, MO United States
  Connect »

CoxHealth South Hospital

Springfield, MO United States
  Connect »

Bozeman Deaconess Hospital

Bozeman, MT United States
  Connect »

Community Medical Hospital

Missoula, MT United States
  Connect »

Long Island Jewish Medical Center

New Hyde Park, NY United States
  Connect »

University of Rochester

Rochester, NY United States
  Connect »

Cleveland Clinic Foundation

Cleveland, OH United States
  Connect »

Mercy Hospital Oklahoma City

Oklahoma City, OK United States
  Connect »

Saint Francis Hospital

Greenville, SC United States
  Connect »

Duluth Clinic Ashland

Ashland, WI United States
  Connect »

Cancer Center of Western Wisconsin

New Richmond, WI United States
  Connect »

Kootenai Medical Center

Coeur d'Alene, ID United States
  Connect »

Saint Joseph Mercy Brighton

Brighton, MI United States
  Connect »

Saint Joseph Mercy Canton

Canton, MI United States
  Connect »

Saint Joseph Mercy Chelsea

Chelsea, MI United States
  Connect »

Sandra L Maxwell Cancer Center

Cedar City, UT United States
  Connect »

Logan Regional Hospital

Logan, UT United States
  Connect »

Riverton Hospital

Riverton, UT United States
  Connect »

LDS Hospital

Salt Lake City, UT United States
  Connect »

Kaiser Permanente Dublin

Dublin, CA United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »